NEW YORK, NY, UNITED STATES, March 18, 2026 /EINPresswire.com/ -- Liv Hospital today launched an informative guide to ...

State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact. At the 2026 ASCO GU meeting, experts gathered to share the ...

Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...

A new international study has found that combining two cancer medicines may significantly slow the growth of a dangerous form ...

A consultant urological surgeon has explained why you need to prepare before a cancer check ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

An NHS diabetes drug costing as little as 2p per table could cut the risk of one of the world's deadliest cancers that's on the rise in the UK, according to a new study.

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in ...

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...